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ABSTRACT
Background The 12-week, phase III Pulmonary
Arterial hyperTENsion sGC-stimulator Trial (PATENT)-1
study investigated riociguat in patients with pulmonary
arterial hypertension (PAH). Here, we present a
prospectively planned analysis of the safety and efﬁcacy
of riociguat in the subgroup of patients with PAH
associated with connective tissue disease (PAH-CTD).
Methods Patients with PAH-CTD were further classiﬁed
post hoc as having PAH associated with systemic sclerosis
or PAH-other deﬁned CTD. In PATENT-1, patients received
riociguat (maximum 2.5 or 1.5 mg three times daily) or
placebo. Efﬁcacy endpoints included change from
baseline in 6-minute walking distance (6MWD; primary
endpoint), haemodynamics and WHO functional class
(WHO FC). In the long-term extension PATENT-2, patients
received riociguat (maximum 2.5 mg three times daily);
the primary endpoint was safety and tolerability.
Results In patients with PAH-CTD, riociguat increased
mean 6MWD, WHO FC, pulmonary vascular resistance
and cardiac index. Improvements in 6MWD and WHO FC
persisted at 2 years. Two-year survival of patients with
PAH-CTD was the same as for idiopathic PAH (93%).
Riociguat had a similar safety proﬁle in patients with
PAH-CTD to that of the overall population.
Conclusions Riociguat was well tolerated and
associated with positive trends in 6MWD and other
endpoints that were sustained at 2 years in patients with
PAH-CTD.
Trial registration numbers PATENT-1
(NCT00810693), PATENT-2 (NCT00863681).
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a com-
plication of connective tissue disease (CTD) that
results from remodelling of the pulmonary vascula-
ture, ultimately leading to right ventricular failure
and death.1–3 Many CTDs can lead to the develop-
ment of PAH (PAH-CTD), including systemic
sclerosis (SSc), systemic lupus erythematosus (SLE)
and mixed CTD.4 Patients with PAH-CTD have a
poorer prognosis compared with patients with idio-
pathic PAH (IPAH), and patients with PAH asso-
ciated with SSc (PAH-SSc) have worse survival rates
than those with non-SSc PAH-CTD.5–7
Recommended treatments for PAH-CTD include
prostanoids, phosphodiesterase type 5 (PDE5)
inhibitors and endothelin receptor antagonists
(ERAs). However, the response to PAH-speciﬁc
therapy is often reduced in patients with PAH-CTD
(particularly PAH-SSc) compared with IPAH.8 9
Riociguat, a soluble guanylate cyclase stimulator,
is approved for the treatment of PAH. In addition to
its vasoactive properties, riociguat has been shown
to have antiﬁbrotic, antiproliferative and anti-
inﬂammatory effects in preclinical models, provid-
ing a rationale for its use in PAH-CTD.10–14 In the
phase III Pulmonary Arterial hyperTENsion sGC-
stimulator Trial (PATENT)-1 study (NCT00810693)
in patients with PAH of various aetiologies, including
patients with PAH-CTD, riociguat was well tolerated
and improved 6-minute walking distance (6MWD)
and several secondary outcomes.15 The improve-
ments in 6MWD and WHO functional class (WHO
FC) were maintained at 2 years in the PATENT-2
open-label extension (NCT00863681).16 Here, we
present a prospectively planned analysis of the safety
and efﬁcacy of riociguat in the subgroup of patients
with PAH-CTD in PATENT-1 and PATENT-2.
METHODS
Patients, study design and outcome measures
The methodologies of the PATENT-1 and PATENT-2
studies are summarised in the online supplementary
appendix. Patients in the prospectively deﬁned PAH-
CTD subgroup were stratiﬁed into three subgroups
(PAH-SSc, PAH-other deﬁned CTD and PAH-
unspeciﬁed CTD) based on MedDRA terms in their
medical history.
Statistical analysis
All analyses were exploratory as PATENT-1 was not
powered to detect signiﬁcant differences in sub-
groups; all data were analysed descriptively. The
primary efﬁcacy analysis was performed on data
from the modiﬁed intention-to-treat population (all
randomised patients who received at least one dose
of study drug). The primary endpoint (6MWD) was
analysed by analysis of covariance to estimate the
least-squares (LS) mean difference and 95% CIs for
riociguat 2.5 mg maximum versus placebo in the
PAH-CTD population. Missing data due to patient
withdrawal or death were imputed at week 12 of
PATENT-1 as previously described,15 except for
haemodynamic endpoints, which were not imputed.
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RESULTS
Patients and baseline characteristics
Of the 443 patients randomised and treated in PATENT-1, 111
patients had PAH-CTD, of whom 66 had PAH-SSc and 39 had
PAH-other deﬁned CTD (18 associated with SLE; 11 associated
with rheumatoid arthritis/disorder; 10 associated with mixed/
other CTD), and 6 had PAH associated with an unspeciﬁed
CTD, as further medical history data were not available. Owing
to low patient numbers, data are not shown for patients with
PAH associated with an unspeciﬁed CTD.
Demographics, baseline characteristics and background
therapy for patients with PAH-CTD in PATENT-1 are shown in
table 1. Patient disposition for the subgroup with PAH-CTD in
PATENT-1 is shown in online supplementary ﬁgure S1. Of the
111 patients with PAH-CTD in PATENT-1, 94 (85%) com-
pleted PATENT-1 and entered PATENT-2. Mean±SD treatment
duration for the PAH-CTD population in PATENT-2 was
31±14 months. For the PAH-SSc and PAH-other deﬁned
CTD subgroups, mean treatment duration was 29±15 months
and 35±12 months, respectively.
Efﬁcacy
The 2.5 mg maximum group
In the PAH-CTD population at week 12, riociguat 2.5 mg
maximum increased mean±SD 6MWD by +18±51 m com-
pared with a decrease of −8±110 m in the placebo group (see
online supplementary ﬁgure S2A) (LS mean treatment differ-
ence: +28 m; 95% CI −4 to 61 m). Patients with PAH-SSc
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Table 1 Disease characteristics and demographics in patients with
PAH-CTD at PATENT-1 baseline
Characteristic
Overall
PAH-CTD
(n=111)
PAH-SSc
(n=66)
PAH-other
defined CTD
(n=39)
Age, mean±SD (years) 57±14 63±11 50±14
Female, n (%) 98 (88) 57 (86) 36 (92)
Time from first diagnosis of PH,
mean±SD (months)
27±36 26±35 26±38
6MWD, mean±SD (m) 352±75 340±76 364±74
WHO FC I/II/III/IV (%)* 5/36/57/2† 2/35/59/3† 10/36/54/0
PAH-specific pretreatment, n (%) 70 (63) 45 (68) 23 (59)
Pretreated with ERA 59 (53) 39 (59) 19 (49)
Pretreated with PCA 10 (9) 6 (9) 3 (8)
Pretreated with ERA and PCA 1 (1) 0 1 (3)
Immunomodulating pretreatment,
n (%)‡
27 (24) 16 (24) 10 (26)
Pretreated with
immunosuppressive agents§
21 (19) 13 (20) 8 (21)
Pretreated with antineoplastic
agents¶
14 (13) 6 (9) 7 (18)
Pretreated with endocrine
therapy**
1 (1) 1 (2) 0
Pretreated with other
immunomodulating agents
1 (1) 0 1 (3)
*Not all percentages add up to 100 due to rounding.
†Data missing for one patient.
‡Non-steroidal anti-inflammatory drugs or disease-modifying antirheumatic drugs.
§Azathioprine, leflunomide, methotrexate, mizoribine, mycophenolate mofetil,
mycophenolate sodium, tacrolimus.
¶Celecoxib, cyclophosphamide, methotrexate.
**Estradiol valerate.
6MWD, 6-minute walking distance; CTD, connective tissue disease; ERA, endothelin
receptor antagonist; PAH, pulmonary arterial hypertension; PCA, prostacyclin analogue;
PH, pulmonary hypertension; SSc, systemic sclerosis; WHO FC, WHO functional class.
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receiving riociguat reported a smaller increase in 6MWD (+4
±43 m), but there was a larger decrease in the placebo group
(−37±120 m) at week 12 (LS mean difference: +43 m; 95% CI
1 to 86 m) (see online supplementary ﬁgure S2B). The
PAH-other deﬁned CTD subgroup showed similar improve-
ments in the riociguat and placebo groups at week 12 (see
online supplementary ﬁgure S2C). Patients who were treatment-
naive, pretreated and patients with concomitant immunosup-
pressant use showed similar changes from baseline in mean±SD
6MWD at week 12 (21±53, 17±50 and 14±63, respectively,
see online supplementary tables S1 and S2). In PATENT-2,
improvements in 6MWD were largely maintained at 2 years in
the PAH-CTD, PAH-SSc and PAH-other deﬁned CTD groups
(see online supplementary ﬁgure S3).
At week 12 in the PAH-CTD population, the proportion of
patients in whom WHO FC had improved or stabilised was
97% in the riociguat group versus 75% in the placebo group
(see online supplementary ﬁgure S4). Results were similar in the
PAH-SSc and PAH-other deﬁned CTD subgroups (see online
supplementary ﬁgure S4). At 2 years of PATENT-2, WHO FC
had improved/stabilised/worsened in 36%/59%/6% of patients
in the PAH-CTD population.
Haemodynamics, N-terminal prohormone of brain natriuretic
peptide (NT-proBNP) and quality-of-life endpoints are shown in
table 2. Riociguat improved pulmonary vascular resistance
(PVR) and cardiac index to a greater extent versus placebo in
the PAH-CTD population (table 2); similar results were seen
in the PAH-SSc and PAH-other deﬁned CTD subgroups,
although the effect was less pronounced in the PAH-SSc sub-
group. No conclusive differences were observed for changes in
mean pulmonary arterial pressure, right atrial pressure and pul-
monary capillary wedge pressure. The efﬁcacy endpoints for rio-
ciguat 2.5 mg maximum from baseline to week 12 in patients
with PAH-CTD who required extra PAH treatment during
PATENT-2 are shown in online supplementary table S3.
As patients with morphea may not have systemic disease, a
sensitivity analysis was performed, excluding three patients
described as having morphea. The results showed similar values
across the main efﬁcacy endpoints to those seen in the overall
PAH-CTD population (see online supplementary table S4).
The 1.5 mg maximum group
Changes in efﬁcacy endpoints in patients with PAH-CTD in the
exploratory riociguat 1.5 mg maximum group are shown in
online supplementary table S5.
Clinical worsening
In PATENT-2, clinical worsening (hospitalisation, decrease in
6MWD or persistent worsening of WHO FC due to pulmonary
hypertension (PH), start of new PH treatment or death)
occurred in 29% of patients with PAH-CTD (see online
supplementary ﬁgure S5) with events occurring more frequently
in the PAH-SSc subgroup (33%) compared with the PAH-other
deﬁned CTD subgroup (24%). Twelve (13%) deaths occurred in
the PAH-CTD population in PATENT-2, six (6%) of whom had
PAH-SSc. At 2 years, survival rates for patients with idiopathic/
familial PAH and PAH-CTD were both 93% (see online
supplementary ﬁgure S6).
Safety
Adverse events (AEs) and serious adverse events (SAEs) occur-
ring in the PAH-CTD population during PATENT-1 are shown
in table 3. The frequency of AEs was comparable in the
PAH-CTD population and the subgroups. No cases of haemop-
tysis or pulmonary haemorrhage occurred in patients with
PAH-CTD in PATENT-1. One (1%) death, resulting from
Table 3 AEs and SAEs in the overall population and in patients with PAH-CTD in PATENT-1
Overall PATENT-1 Overall PAH-CTD PAH-SSc PAH-other defined CTD
Riociguat (all
doses) (n=317)
Placebo
(n=126)
Riociguat (all
doses) (n=86)
Placebo
(n=25)
Riociguat (all
doses) (n=50)
Placebo
(n=16)
Riociguat (all
doses) (n=33)
Placebo
(n=6)
Any AE 285 (90) 108 (86) 82 (95) 24 (96) 49 (98) 15 (94) 30 (91) 6 (100)
AEs experienced by ≥20% patients in any CTD group
Headache 89 (28) 25 (20) 26 (30) 9 (36) 16 (32) 8 (50) 7 (21) 1 (17)
Nausea 50 (16) 16 (13) 21 (24) 3 (12) 12 (24) 3 (19) 8 (24) 0
Peripheral oedema 58 (18) 14 (11) 16 (19) 5 (20) 11 (22) 2 (13) 5 (15) 2 (33)
Dizziness 55 (17) 15 (12) 15 (17) 3 (12) 12 (24) 1 (6) 3 (9) 1 (17)
Diarrhoea 41 (13) 13 (10) 13 (15) 6 (24) 9 (18) 4 (25) 3 (9) 1 (17)
Anaemia 22 (7) 3 (2) 12 (14) 3 (12) 10 (20) 2 (13) 2 (6) 1 (17)
Pyrexia 14 (4) 4 (3) 10 (12) 1 (4) 5 (10) 0 4 (12) 1 (17)
Discontinuation due to AE 9 (3) 9 (7) 3 (3) 4 (16) 3 (6) 4 (25) 0 0
AEs of special interest
Hypotension 27 (9) 3 (2) 9 (10) 1 (4) 8 (16) 0 1 (3) 1 (17)
Syncope 3 (1) 5 (4) 1 (1) 0 1 (2) 0 0 0
Any SAE 40 (13) 23 (18) 14 (16) 7 (28) 10 (20) 5 (31) 4 (12) 2 (33)
SAEs experienced by ≥5% patients in any CTD group
Right ventricular failure 5 (2) 1 (1) 2 (2) 1 (4) 1 (2) 1 (6) 1 (3) 0
Dyspnoea 0 1 (1) 0 1 (4) 0 1 (6) 0 0
Worsening PAH 2 (1) 2 (2) 0 2 (8) 0 2 (13) 0 0
Discontinuation due to SAE 5 (2) 7 (6) 1 (1) 3 (12) 1 (2) 3 (19) 0 0
Deaths 3 (1) 3 (2) 0 1 (4) 0 1 (6) 0 0
AE, adverse event; CTD, connective tissue disease; PAH, pulmonary arterial hypertension; SAE, serious adverse event; SSc, systemic sclerosis.
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worsening PH, was reported in a patient with PAH-SSc receiv-
ing placebo.
AEs, SAEs and discontinuations were similar for the overall
PATENT-2 population and the PAH-CTD subgroup, although
most AEs occurred more frequently in patients with PAH-CTD
and patients with concomitant immunosuppressant use (see
online supplementary table S6). The most common SAEs in the
pooled riociguat groups in the PAH-CTD population were
pneumonia (3%) and right ventricular failure (2%). In
PATENT-2, 1 (1%) patient with PAH-CTD experienced an SAE
of haemoptysis compared with 13 (3%) patients in the overall
population. A similar safety proﬁle to that of the PAH-CTD
population was observed in the subgroups.
DISCUSSION
Riociguat improved several efﬁcacy endpoints in patients with
PAH-CTD including 6MWD, WHO FC, PVR and cardiac
index, although improvements were less pronounced than in the
overall PATENT-1 population. This is consistent with previous
observations that patients with PAH-CTD respond less well to
PAH-speciﬁc therapy than patients with IPAH.4 6 The efﬁcacy
results presented in this analysis appear comparable with previ-
ous trials of patients with PAH-CTD treated with prostacy-
clins,17 ERAs18 and PDE5 inhibitors,8 although comparison
between trials requires caution.
Less pronounced improvements in 6MWD were seen in
patients with PAH-SSc; however, signiﬁcant deterioration was
observed in the PAH-SSc placebo group, suggesting that rioci-
guat may prevent worsening of 6MWD in these patients. A sep-
arate study investigating riociguat in diffuse cutaneous SSc is
ongoing (NCT02283762).
The improvements in 6MWD observed in patients that were
pretreated with ERAs (53% of the PAH-CTD population)
suggest that riociguat may provide additional therapeutic bene-
ﬁts in patients with PAH-CTD receiving ERAs, supporting the
potential use of combination therapy in this subgroup.
With over 2 years of riociguat treatment in PATENT-2, sur-
vival of patients with PAH-CTD was similar to that seen in
patients with idiopathic/familial PAH in PATENT-2 (93%).16
This is an important observation as mortality for PAH-CTD has
been previously reported to be higher than IPAH despite
modern therapy.19
The data in this analysis should be considered exploratory as
PATENT-1 and PATENT-2 were not designed to detect statisti-
cally signiﬁcant differences in subgroups. Moreover, the analysis
is limited due to the post hoc subclassiﬁcation of patients with
PAH-CTD by patients’ medical histories using MedDRA terms.
Also, as with most long-term trial data, it is possible that the
analyses of long-term outcomes are subject to survivor bias.
Finally, the low patient numbers in the PAH-SSc and PAH-other
deﬁned CTD subgroups should be taken into consideration
when interpreting the data.
In conclusion, riociguat was well tolerated in patients with
PAH-CTD and led to improvement or stabilisation in 6MWD,
WHO FC and haemodynamics. The 2-year survival rate of
patients with PAH-CTD or PAH-SSc was similar to that of
patients with idiopathic/familial PAH.
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